New drug combo could make kidney cancer surgery safer
NCT ID NCT05969496
First seen Apr 14, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests whether giving two drugs (pembrolizumab and axitinib) before surgery can shrink tumor-related blood clots in the main vein of people with kidney cancer. The goal is to make surgery easier and safer, and to improve long-term outcomes. About 17 adults with clear cell kidney cancer and a clot in the inferior vena cava will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hilands Ranch Hospital
RECRUITINGHighlands Ranch, Colorado, 80129, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lone Tree Medical Center
RECRUITINGLone Tree, Colorado, 80124, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Cancer Center
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.